Roche CEO Is Optimistic on Coming Alzheimer's Trial Results.

Roche Holding AG's CEO, Thomas Schinecker, is optimistic about the potential benefits of the company's experimental Alzheimer's drug, which has shown promise in breaking up amyloid plaques associated with the disease. The drugmaker will present data from a patient trial at an upcoming medical conference. Roche is focusing on its experimental medicines to drive growth following setbacks in Alzheimer's research, with third-quarter sales showing positive results in various therapeutic areas. The company remains confident in its future prospects, despite challenges in certain product lines. [Extracted from the article]